CN101449822A - Embryo telomerase food - Google Patents
Embryo telomerase food Download PDFInfo
- Publication number
- CN101449822A CN101449822A CNA2007101941801A CN200710194180A CN101449822A CN 101449822 A CN101449822 A CN 101449822A CN A2007101941801 A CNA2007101941801 A CN A2007101941801A CN 200710194180 A CN200710194180 A CN 200710194180A CN 101449822 A CN101449822 A CN 101449822A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- embryonic stem
- embryo
- people
- telomerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides embryo telomere enzyme which belongs to field of health product and overcomes disadvantage that life-prolonging function of A-type telomere enzyme is not utilized by a traditional stem cell therapy. The main technology characteristic of the present invention is that function of the A-type telomere enzyme in embryonic stem cell freeze-drying powder is to make human nucleus chromosome telomere greatly increase split algebraically of each differentiation cell and stem cell of human body and to make people health and longevity. The invention prolongs life span radically.
Description
1, the invention belongs to field of health care products.
2, (1) Chemical Industry Press May in 2006 the 1st edition, Zhao Chunhua edits " stem cell principle, technology and clinical ".Say for the 27th page: telomere is to be positioned at the reiterated DNA sequences that chromosome is not held, and 50～100bp is shortened in cell division each time.In embryonic tissue, Telomerase is highly to express, and has the high level activity.Telomerase is repaired the telomere that chromosome is not held.Say in the 14th page: but the embryonic stem cell infinite multiplication.It will be argued that the highly active Telomerase in people and the mammiferous embryonic stem cell is called for short A type Telomerase.From the above, A type Telomerase can make infinitely or chronically somatoblast of telomere, increases cell division algebraically, increases man's lifespan, and the people is recovered one's youthful vigour.(2) conventional dry cell therapy is only known the differentiation function that utilizes stem cell, does not know to utilize the strong function of lengthening the life of the A type Telomerase in the embryonic stem cell.
3, Fa Ming purpose is with A type Telomerase the people to be had good health and a long life.
4, the composition of embryo telomerase food is inside and outside people or mammiferous embryo, the embryonic stem cell of division, propagation, and it is characterized in that: (one) isolates embryonic stem cell from people or mammiferous embryo; At a large amount of divisions in external nothing differentiation ground, propagation embryonic stem cell; Embryonic stem cell is made the embryonic stem cell freeze-dried powder through the two refrigerating process of ultralow temperature, pours into capsule again.(2) function of the A type Telomerase in the embryonic stem cell freeze-dried powder is to make people's nucleus chromosome telomere increase each noble cells of human body, the division algebraically of each stem cell greatly, and the people is had good health and a long life; The function of the strong vitality material of other in the embryonic stem cell freeze-dried powder is to cure the disease, remove free radical, beauty treatment, anti-ageing.(3) also aseptic virus-free embryonic stem cell can be made the health care injection.
5, the present invention has overcome the shortcoming that the conventional dry cell therapy is not utilized A type Telomerase life-prolonging function, fundamentally solves the problem of promoting longevity, and has world's advance.
Claims (1)
1, the composition of embryo telomerase food is inside and outside people or mammiferous embryo, the embryonic stem cell of division, propagation, and it is characterized in that: (one) isolates embryonic stem cell from people or mammiferous embryo; At a large amount of divisions in external nothing differentiation ground, propagation embryonic stem cell; Embryonic stem cell is made the embryonic stem cell freeze-dried powder through the two refrigerating process of ultralow temperature, pours into capsule again.(2) function of the A type Telomerase in the embryonic stem cell freeze-dried powder is to make people's nucleus chromosome telomere increase each noble cells of human body, the division algebraically of each stem cell greatly, and the people is had good health and a long life; The function of the strong vitality material of other in the embryonic stem cell freeze-dried powder is to cure the disease, remove free radical, beauty treatment, anti-ageing.(3) also aseptic virus-free embryonic stem cell can be made the health care injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101941801A CN101449822A (en) | 2007-12-05 | 2007-12-05 | Embryo telomerase food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101941801A CN101449822A (en) | 2007-12-05 | 2007-12-05 | Embryo telomerase food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101449822A true CN101449822A (en) | 2009-06-10 |
Family
ID=40732452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101941801A Pending CN101449822A (en) | 2007-12-05 | 2007-12-05 | Embryo telomerase food |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101449822A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9364425B2 (en) | 2012-03-19 | 2016-06-14 | Richard Burt | Methods and compositions for regenerating and repairing damaged or aged tissue or organs using nonviable irradiated or lyophilized pluripotent stem cells |
| RU2640487C1 (en) * | 2016-11-02 | 2018-01-09 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Method for estimation of biomedical cellular products safety |
| US9867855B2 (en) | 2006-07-20 | 2018-01-16 | Richard Burt | Method of using mitotically inactivated stem cells for damaged tissue repair |
| US10813955B2 (en) | 2015-09-29 | 2020-10-27 | Genani Corporation | Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells |
-
2007
- 2007-12-05 CN CNA2007101941801A patent/CN101449822A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9867855B2 (en) | 2006-07-20 | 2018-01-16 | Richard Burt | Method of using mitotically inactivated stem cells for damaged tissue repair |
| US9364425B2 (en) | 2012-03-19 | 2016-06-14 | Richard Burt | Methods and compositions for regenerating and repairing damaged or aged tissue or organs using nonviable irradiated or lyophilized pluripotent stem cells |
| US9381151B2 (en) | 2012-03-19 | 2016-07-05 | Richard Burt | Methods and compositions for regenerating and repairing damaged or aged tissue or organs using nonviable irradiated or lyophilized pluripotent stem cells |
| US9757422B2 (en) | 2012-03-19 | 2017-09-12 | Richard K. Burt | Methods and compositions for regenerating and repairing damaged or aged tissue or organs using nonviable irradiated or lyophilized pluripotent stem cells |
| US10813955B2 (en) | 2015-09-29 | 2020-10-27 | Genani Corporation | Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells |
| US10828338B2 (en) | 2015-09-29 | 2020-11-10 | Genani Corporation | Methods for improving cognition and slowing cognitive impairment using nonviable lyophilized pluripotent stem cells |
| RU2640487C1 (en) * | 2016-11-02 | 2018-01-09 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Method for estimation of biomedical cellular products safety |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009012666A (en) | Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue. | |
| TR201903587T4 (en) | Compounds for increasing telomerase activity. | |
| WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
| MX2009012650A (en) | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders. | |
| WO2006014729A3 (en) | Inhibitors of angiopoietin-like 4 protein, combinations, and their use | |
| EP2298861A3 (en) | Mesenchymal stem cells and uses therefor | |
| ATE526975T1 (en) | PKR ACTIVATION USING HYBRIDIZATION CHAIN REACTION | |
| WO2009028870A3 (en) | Composition for the diagnosis, prevention or treatment of diseases related to cells expressing il-8 or gro-alpha, comprising ucb-mscs | |
| NZ608734A (en) | Bone marrow derived cd271 precursor cells for cardiac repair | |
| CN101449822A (en) | Embryo telomerase food | |
| WO2010127342A3 (en) | Method of preparing autologous cells and method of use for therapy | |
| TWI702055B (en) | Pachyrhizus erosus fermented extracts and the use thereof for enhancing the gene expression of col, timp, lox, eln, has, sod, tcp1 and ung, and for reducing the skin melanin content | |
| BRPI0415563A (en) | method for treating parkinson's disease, use of a viral vector, viral expression vector, pharmaceutical composition, isolated host cell, packaging cell line, chimeric non-human mammal, implantable cell culture device, biocompatibly capsule, method for treatment of a nervous system disease, mammalian cell, and, method for producing neurturin or a functional equivalent thereof | |
| SG11201900986YA (en) | Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells | |
| KR101867620B1 (en) | Platelet-derived growth factor-bb production promoter, and mesenchymal stem cell production accelerator, stem cell stabilizer and dermal regenerator comprising the same | |
| MX2007015127A (en) | Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation. | |
| WO2006113731A3 (en) | Bone marrow-derived neurogenic cells and uses thereof | |
| CN104004711B (en) | A kind of improve the human mesenchymal stem cell method to Osteoblast Differentiation ability | |
| WO2003106648A3 (en) | Compositions and methods relating to breast specific genes and proteins | |
| CN113384579B (en) | Pharmaceutical composition and application thereof in delaying senescence | |
| Zhao et al. | Why cell reprogramming is functionally linked to aging? | |
| Ll et al. | The Therapeutic Efficacy of Adipose Tissue-Derived Mesenchymal Stem Cell Conditioned Medium on Experimental Colitis Was Improved by the Serum From Colitis Rats. Front. Bioeng. Biotechnol. 9: 694908. doi: 10.3389/fbioe. 2021.694908 | |
| Abdel-Hay et al. | The Interplay between Mesenchymal Stem Cells and MicroRNA-133 in Type 1 Diabetic Rats | |
| UY28605A1 (en) | USE OF ENOS TRANSCRIPTION IMPROVERS IN THE CELLULAR THERAPY OF ISCHEMICAL HEART DISEASES. | |
| RU2006100561A (en) | METHOD FOR TREATING ONCOLOGICAL DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090610 |